Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • CDSCO issues...

    CDSCO issues regulatory pathway for R&D of IVD kit for diagnosis of COVID-19

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-03-24T11:45:00+05:30  |  Updated On 24 March 2020 1:35 PM IST
    CDSCO issues regulatory pathway for R&D of IVD kit for diagnosis of COVID-19

    Delhi: Through the recent notice Central Drugs Standard Control Organization(CDSCO), Directorate General of Health Services as apprised about the regulatory pathway for R&D of IVD kit for diagnosis of COVID-19.

    Novel Corona-virus Disease (COVID-19) has spread over 118 countries with now more than 191.127 cases and 7807 people have lost their lives as on 18.03.2020. World Health Organization (WHO) has declared it as pandemic. However, there is no current evidence from randomized clinical trials to recommend any specific treatment for suspected or confirmed patients with COVID-19. In order to encourage research & development of in-vitro diagnostic kits for diagnosis of COVID-19, any application submitted to CDSCO will be processed on high priority. CDSCO will also provide guidance on a regulatory pathway on such matters. The details are as under -

    1. Any firm having an In-vitro Diagnostic Kit under development for COVID-19 can directly approach DCG(I) through the Public Relations Office for seeking guidance for the regulatory pathways.

    2. Any firm having In-vitro Diagnostic Kit already approved for COVID-19 in any other country can directly approach DCG(I) through Public Relations Office regarding expedited review accelerated approval for marketing in India.

    3. Data requirement for clinical performance evaluation, etc. may be abbreviated, deferred, or waived on case to case basis depending on the type & nature of the diagnostic kit, existing data on the product and evidence of available clinical performance evaluation data of such kit.

    4. Applications to manufacture or import In-vitro Diagnostic Kit for test, evaluation and further use in performance evaluation may be processed on priority within 7 days.

    5. Application for conducting performance evaluation and applications to import or manufacture In-vitro Diagnostic Kit for sale and distribution would be processed on priority through the expedited review/accelerated approval

    For any additional information contact Public Relations Office through toll-free number 1800 11 1454 & write to startupinnov@cdsco.nicin .

    For full details click on the link given below

    Read also: https://business.medicaldialogues.in/pdf_upload/pdf_upload-125778.pdf

    cdscodcgicoronaviruscovid-19whocentral-drugs-standard-control-organizationin-vitro-diagnostic-kit

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok